Noah Nasser, CEO of datma
Noah Nasser is CEO of datma, a leading provider of federated Real-World Data platforms and related analytical tools. With more than twenty-five years of experience in biotechnology, Noah brings a broad background in developing and commercializing novel technology to advance human health, including serving as the CEO of Serimmune and Chief Commercial Officer roles at Human Longevity and Counsyl. Noah led Counsyl’s commercial team through its acquisition in 2018 by Myriad Genetics. He previously held senior leadership positions at AltheaDx and Verinata Health, a leader in non-invasive prenatal testing (NIPT), where he led his team through the company’s 2013 acquisition by Illumina. He holds a B.S. from the University of California, San Diego in Molecular Biology.
Company:datma
datma empowers healthcare providers, clinicians, and researchers to unlock insights from Real-World Data. datma's federated platform, datma.FED, enables secure, privacy-preserving collaboration, helping data custodians and consumers drive innovation and improve patient outcomes globally.
